About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon Quarterly Results
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Financials

Financial Results

 
 
 
  FY 17-18 Q1 H1 9M FY
  Notice Ad Notice Ad Q1 FY 2017-18 Notice Ad H1 FY 2017-18 Notice Ad H1 FY 2017-18 Notice Ad FY 2017-18
  Press Release Biocon_Q1 FY18_Press Release Biocon_Q1 FY18_Press Release Press Release 9M 2017-18 Biocon_Q1 FY18_Press Release
  Fact Sheet Biocon Fact Sheet - Summary Q1 FY18_Cr Biocon_Q1 FY18_Press Release Fact sheet 9M 2017-18 Fact sheet 9M 2017-18
  Transcript of the Call Transcript Biocon Earnings 28 July 2017 Biocon_Q1 FY18_Press Release Biocon_Q1 FY18_Press Release Biocon_Q1 FY18_Press Release
  Newspaper Advertisement Transcript Biocon Earnings 28 July 2017 Biocon_press_releases_261017 Newspaper Advertisement 2018 Newspaper Advertisement 2018
  Results Transcript Biocon Earnings 28 July 2017 Biocon_press_releases_261017 Q3-18-Signed-LR-&-Results Q3-18-Signed-LR-&-Results
  Investor Presentation

Consolidated Financial Performance (FY2018-FY2017)

As per IND-AS In Rs Crore, except growth numbers
Particulars  FY18 FY17
Income
 Small Molecules 1,508 1,641
 Biologics 770 702
 Branded
 Formulations
612 549
 Research Services 1,423 1,193
Inter Segment (183) (163)
Revenue from operations* 4,130 3,922
Other Income 206 157
TOTAL REVENUE 4,336 4,079
EBITDA 1,035 1,137
Interest and Finance charges 61 26
Depreciation & Amortisation 385 277
Exceptional Item (Net) (8)
PBT 610 850
Net Profit 372 612
R&D Expenses in P&L 216 267
Gross R&D Spends 380 402
EBITDA Margin 24% 28%
Core EBITDA Margin 27% 32%
Net Profit Margin 9% 15%
*includes Licensing Income 23 145
Notes: Figures above are rounded off to the nearest Cr; % based on absolute numbers.

Year 2017-18 Financial Highlights

In Rs. Crore 
  FY 17-18 Q1 H1 9M FY
  Revenue 988 1019 1092 1237
  EBITDA 246 233 256 300
  Net Profit 81 69 92 130
  R&D Expenses in P&L 58 54 53 51
  Total R&D Spends 96 93 94 98
  EBITDA Margins 25% 23% 23% 24%
  Core EBITDA Margin 29% 27% 27% 26%
  Net Profit Margins 8% 7% 8% 11%
 
  * As per IND-AS  
  FY15-16  FY15-16  FY14-15  FY13-14  FY12-13  FY11-12  FY10-11  FY09-10  FY08-09  FY07-08  FY06-07  FY05-06  FY04-05 

 
Quarterly Results
 FY17-18
 FY16-17
 FY15-16
 FY14-15
 FY13-14
 FY12-13
 FY11-12
 FY10-11
 FY09-10
 FY08-09
 FY07-08
 FY06-07
 FY05-06
 FY04-05
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved